Viking Therapeutics (VKTX) Assets Average (2016 - 2026)
Viking Therapeutics (VKTX) has disclosed Assets Average for 12 consecutive years, with $662.0 million as the latest value for Q1 2026.
- For Q1 2026, Assets Average fell 25.42% year-over-year to $662.0 million; the TTM value through Mar 2026 reached $662.0 million, down 25.42%, while the annual FY2025 figure was $812.0 million, 27.2% up from the prior year.
- Assets Average hit $662.0 million in Q1 2026 for Viking Therapeutics, down from $727.6 million in the prior quarter.
- Across five years, Assets Average topped out at $957.2 million in Q2 2024 and bottomed at $159.7 million in Q1 2023.
- Average Assets Average over 5 years is $549.1 million, with a median of $662.0 million recorded in 2026.
- Year-over-year, Assets Average soared 318.26% in 2024 and then fell 25.42% in 2026.
- Viking Therapeutics' Assets Average stood at $167.6 million in 2022, then surged by 124.08% to $375.6 million in 2023, then soared by 145.78% to $923.1 million in 2024, then dropped by 21.18% to $727.6 million in 2025, then decreased by 9.01% to $662.0 million in 2026.
- According to Business Quant data, Assets Average over the past three periods came in at $662.0 million, $727.6 million, and $783.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.